PRAX - Praxis Precision Medicines

-

$undefined

N/A

(N/A)

Praxis Precision Medicines NasdaqGS:PRAX Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

Location: 99 High Street, Boston, MA, 02110, United States | Website: https://praxismedicines.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

456.3M

Cash

328M

Avg Qtr Burn

-40.98M

Short % of Float

11.97%

Insider Ownership

0.16%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Vormatrigine (PRAX-628) Details
Epilepsy, Focal Onset Seizures

Phase 2/3

Data readout

Vormatrigine (PRAX-628) Details
Epilepsy, Focal Onset Seizures

Susp. Mover™

Phase 2b

Data readout

Vormatrigine (PRAX-628) Details
Epilepsy, Focal Onset Seizures

Phase 2b

Update

PRAX-562 Details
Developmental and Epileptic Encephalopathy

Phase 2

Data readout

Phase 2

Update

PRAX-222 Details
Developmental and Epileptic Encephalopathy

Phase 1/2

Data readout

Failed

Discontinued

Failed

Discontinued